|
| 產(chǎn)地 | 進口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10092 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-OPGL/RANKL/ODF |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human OPGL C-terminus |
產(chǎn)品訂購信息：
英文名稱 Anti-OPGL/RANKL/ODF
中文名稱 骨保護蛋白配體抗體(破骨細胞分化因子)說明書
別 名 CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog
產(chǎn)品類型 一抗
研究領(lǐng)域 細胞生物 免疫學 發(fā)育生物學
蛋白分子量 predicted molecular weight: 35kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human OPGL C-terminus
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
骨保護蛋白配體抗體(破骨細胞分化因子)說明書 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
Function : Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
Subcellular Location : Cytoplasm; Secreted and Cell membrane.
Tissue Specificity : Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
Post-translational modifications : The soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.
DISEASE : Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.
Similarity : Belongs to the tumor necrosis factor family.
Database links : UniProtKB/Swiss-Prot: O14788.1
Entrez Gene: 8600 Human
Entrez Gene: 21943 Mouse
Omim: 602642 Human
SwissProt: O14788 Human
SwissProt: O35235 Mouse
Unigene: 333791 Human
Unigene: 249221 Mouse
OPGL骨保護蛋白配體又稱骨保護素配體(破骨細胞發(fā)育刺激因子)。屬TNF-a家族。
OPGL促進破骨細胞的分化和活性,而OPG抑制這些過程。細胞影響骨髓中這兩種蛋白的生理平衡，是發(fā)生溶骨性的根本所在。
HIF-1Alpha (Hypoxia-inducible factor -1Alpha) 缺氧誘導因子1α (抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-CD166/ALCAM/MEMD 活化白細胞粘附分子抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh PAR3 蛋白酶激活受體3抗體 規(guī)格 0.2ml
TREM2 Kit Human 人 TREM-2 / TREM2 ELISA配對抗體 ELISA
phospho-TPH (Ser260) 英文名稱： 磷酸化色酸羥化酶抗體 0.1ml
NT5C2 英文名稱： 胞漿-5′-核苷酸酶-Ⅱ抗體 0.1ml
Anti-CD166/ALCAM/MEMD 活化白細胞粘附分子抗體Multi-class antibodies規(guī)格： 0.2ml
HHV8/ORF K2/vIL-6(Human herpesvirus 8) 人類病毒8抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-CD163/M130 CD163抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh PAR3 型蛋白激酶C特定相互作用蛋白抗體 規(guī)格 0.1ml
NOV Kit Human 人 CCN3 / NOV / IGFBP9 ELISA配對抗體 ELISA
TPA 英文名稱： 組織型纖溶酶原激活劑抗體 0.1ml
CD86 英文名稱： CD86抗體 0.1ml
Anti-CD163/M130 CD163抗體Multi-class antibodies規(guī)格： 0.2ml
NN-T4 ELISA Kit 大鼠新生甲狀腺素Multi-class antibodies規(guī)格： 48T
Anti-ATPase Na+/K+protein/FITC 熒光素標記ATP酶通道蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh F-Actin 纖維狀肌動蛋白抗體 規(guī)格 0.1ml
sCD30(Mouse soluble cluster of differentiation 30) Elisa Kit 小鼠可溶性CD30 96T
music Acetylcholine Receptor 1 英文名稱： 毒蕈堿型乙酰膽堿受體M1抗體 0.1ml
Gamma-Adaptin 英文名稱： 銜接蛋白γ/γ-Adaptin抗體 0.1ml
Anti-ATPase Na+/K+protein/FITC 熒光素標記ATP酶通道蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
TDGF1 Protein Rat 重組大鼠 Cripto / TDGF1 蛋白 (Fc 標簽)
LS174T 人細胞
CD6 Others Mouse 小鼠 CD6 / TP120 人細胞裂解液 (陽性對照)
MDA-MB-231人癌細胞 Human breast cancer cell line MDA-MB-231 L-15+10% Hyclone FBS
T739小鼠肺腺株;LA795
人羊膜細胞;WISH SGC-7901, 人胃腺癌細胞系 Human
CL-0303PATU8988(人*癌細胞)5×106cells/瓶×2
CD40LG Others Canine 狗 CD40L / CD154 / TNFSF5 人細胞裂解液 (陽性對照)
人平滑肌細胞總RNAHBVSMC tDNA
山羊皮膚成纖維樣細胞;DG-S1 胚腎細胞，AAV-293細胞 HP615細胞，615小鼠瘤株
人干細胞因子單克隆抗體細胞株;AMS2(SCF3)
HA Others H5N1 甲型 H5N1 (A/Common magpie/Hong Kong/2256/2006) 血凝素 (Hemagglutinin / HA) 人細胞裂解液 (陽性對照)
骨保護蛋白配體抗體(破骨細胞分化因子)說明書 TDGF1 Protein Rat 重組大鼠 Cripto / TDGF1 蛋白 (Fc 標簽)
LS174T 人細胞
CD6 Others Mouse 小鼠 CD6 / TP120 人細胞裂解液 (陽性對照)
MDA-MB-231人癌細胞 Human breast cancer cell line MDA-MB-231 L-15+10% Hyclone FBS
T739小鼠肺腺株;LA795
人羊膜細胞;WISH SGC-7901, 人胃腺癌細胞系 Human
抗體的生物素化標記實驗要點：
1. 骨保護蛋白配體抗體(破骨細胞分化因子)說明書 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。
抗體的鑒定：
1）骨保護蛋白配體抗體(破骨細胞分化因子)說明書 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
|
|
|
|
|
